ARCUS BIOSCIENCES INC (RCUS) Stock Fundamental Analysis
USA - NYSE:RCUS - US03969F1093 - Common Stock
17.31 USD
+0.53 (+3.16%)
17.56 USD
+0.25 (+1.44%)
RCUS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. RCUS may be in some trouble as it scores bad on both profitability and health. RCUS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RCUS had negative earnings in the past year.
In the past year RCUS has reported a negative cash flow from operations.
In the past 5 years RCUS reported 4 times negative net income.
In multiple years RCUS reported negative operating cash flow during the last 5 years.
1.2 Ratios
RCUS has a better Return On Assets (-27.72%) than 70.41% of its industry peers.
RCUS has a better Return On Equity (-54.28%) than 64.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.72% | ||
| ROE | -54.28% | ||
| ROIC | N/A |
ROA(3y)-24.17%
ROA(5y)-17.02%
ROE(3y)-55.15%
ROE(5y)-36.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RCUS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RCUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RCUS has been increased compared to 1 year ago.
The number of shares outstanding for RCUS has been increased compared to 5 years ago.
RCUS has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.44, we must say that RCUS is in the distress zone and has some risk of bankruptcy.
RCUS has a Altman-Z score of 0.44. This is comparable to the rest of the industry: RCUS outperforms 59.74% of its industry peers.
RCUS has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
RCUS's Debt to Equity ratio of 0.18 is on the low side compared to the rest of the industry. RCUS is outperformed by 67.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.44 |
ROIC/WACCN/A
WACC9.33%
2.3 Liquidity
RCUS has a Current Ratio of 4.50. This indicates that RCUS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.50, RCUS is in line with its industry, outperforming 49.81% of the companies in the same industry.
RCUS has a Quick Ratio of 4.50. This indicates that RCUS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of RCUS (4.50) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.5 | ||
| Quick Ratio | 4.5 |
3. Growth
3.1 Past
The earnings per share for RCUS have decreased by -2.59% in the last year.
The Revenue has been growing slightly by 6.07% in the past year.
Measured over the past years, RCUS shows a very strong growth in Revenue. The Revenue has been growing by 76.65% on average per year.
EPS 1Y (TTM)-2.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)6.07%
Revenue growth 3Y-12.33%
Revenue growth 5Y76.65%
Sales Q2Q%310.26%
3.2 Future
RCUS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.45% yearly.
The Revenue is expected to grow by 25.56% on average over the next years. This is a very strong growth
EPS Next Y-24.01%
EPS Next 2Y-17.73%
EPS Next 3Y-7.58%
EPS Next 5Y9.45%
Revenue Next Year-11.35%
Revenue Next 2Y-24.59%
Revenue Next 3Y-8.38%
Revenue Next 5Y25.56%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RCUS. In the last year negative earnings were reported.
Also next year RCUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RCUS's earnings are expected to decrease with -7.58% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.73%
EPS Next 3Y-7.58%
5. Dividend
5.1 Amount
No dividends for RCUS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
17.31
+0.53 (+3.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners66.06%
Inst Owner Change-0.01%
Ins Owners5.33%
Ins Owner Change0.24%
Market Cap1.84B
Revenue(TTM)262.00M
Net Income(TTM)-298000000
Analysts82.11
Price Target29.77 (71.98%)
Short Float %14.27%
Short Ratio10.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)45.79%
Min EPS beat(2)-8.41%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)29.62%
Min EPS beat(4)-8.41%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)29.65%
EPS beat(12)10
Avg EPS beat(12)23.51%
EPS beat(16)12
Avg EPS beat(16)53.99%
Revenue beat(2)1
Avg Revenue beat(2)186.2%
Min Revenue beat(2)-24.87%
Max Revenue beat(2)397.27%
Revenue beat(4)2
Avg Revenue beat(4)96.47%
Min Revenue beat(4)-24.87%
Max Revenue beat(4)397.27%
Revenue beat(8)6
Avg Revenue beat(8)97.14%
Revenue beat(12)8
Avg Revenue beat(12)71.78%
Revenue beat(16)10
Avg Revenue beat(16)102.09%
PT rev (1m)0%
PT rev (3m)3.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.11%
EPS NY rev (1m)0%
EPS NY rev (3m)17.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-22.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)97.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.03 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.36 | ||
| P/tB | 3.36 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.17
EYN/A
EPS(NY)-4.3
Fwd EYN/A
FCF(TTM)-3.21
FCFYN/A
OCF(TTM)-3.19
OCFYN/A
SpS2.46
BVpS5.16
TBVpS5.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.72% | ||
| ROE | -54.28% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-24.17%
ROA(5y)-17.02%
ROE(3y)-55.15%
ROE(5y)-36.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 30% | ||
| Cap/Sales | 1.15% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.5 | ||
| Quick Ratio | 4.5 | ||
| Altman-Z | 0.44 |
F-Score1
WACC9.33%
ROIC/WACCN/A
Cap/Depr(3y)153.33%
Cap/Depr(5y)249.37%
Cap/Sales(3y)9.4%
Cap/Sales(5y)7.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-24.01%
EPS Next 2Y-17.73%
EPS Next 3Y-7.58%
EPS Next 5Y9.45%
Revenue 1Y (TTM)6.07%
Revenue growth 3Y-12.33%
Revenue growth 5Y76.65%
Sales Q2Q%310.26%
Revenue Next Year-11.35%
Revenue Next 2Y-24.59%
Revenue Next 3Y-8.38%
Revenue Next 5Y25.56%
EBIT growth 1Y-23.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.25%
EBIT Next 3Y-2.73%
EBIT Next 5YN/A
FCF growth 1Y-8.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.89%
OCF growth 3YN/A
OCF growth 5YN/A
ARCUS BIOSCIENCES INC / RCUS FAQ
What is the ChartMill fundamental rating of ARCUS BIOSCIENCES INC (RCUS) stock?
ChartMill assigns a fundamental rating of 2 / 10 to RCUS.
What is the valuation status of ARCUS BIOSCIENCES INC (RCUS) stock?
ChartMill assigns a valuation rating of 0 / 10 to ARCUS BIOSCIENCES INC (RCUS). This can be considered as Overvalued.
What is the profitability of RCUS stock?
ARCUS BIOSCIENCES INC (RCUS) has a profitability rating of 1 / 10.
What is the expected EPS growth for ARCUS BIOSCIENCES INC (RCUS) stock?
The Earnings per Share (EPS) of ARCUS BIOSCIENCES INC (RCUS) is expected to decline by -24.01% in the next year.